{
    "clinical_study": {
        "@rank": "31897", 
        "acronym": "INDIGO", 
        "arm_group": {
            "arm_group_label": "LUM001", 
            "arm_group_type": "Experimental", 
            "description": "LUM001 administered orally once each day"
        }, 
        "brief_summary": {
            "textblock": "This is an open label study in children with Progressive Familial Intrahepatic Cholestasis\n      (PFIC) designed to evaluate the safety and efficacy of LUM001.  Efficacy will be assessed by\n      evaluating the effect of LUM001 on the biochemical markers and pruritus associated with\n      PFIC."
        }, 
        "brief_title": "Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Progressive Familial Intrahepatic Cholestasis (PFIC)", 
        "condition_browse": {
            "mesh_term": [
                "Cholestasis", 
                "Cholestasis, Intrahepatic", 
                "Liver Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosis of Progressive Familial Intrahepatic Cholestasis\n\n          2. Ability to understand and willingness to sign informed consent/assent prior to\n             initiation\n\n        Exclusion Criteria:\n\n          1. Surgical disruption of the enterohepatic circulation\n\n          2. Liver transplant\n\n          3. History or presence of other concomitant liver disease\n\n          4. Females who are pregnant or lactating"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Months"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057718", 
            "org_study_id": "LUM001-501", 
            "secondary_id": "2013-003833-14"
        }, 
        "intervention": {
            "arm_group_label": "LUM001", 
            "intervention_name": "LUM001", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 5, 2014", 
        "link": {
            "url": "http://www.lumenapharma.com"
        }, 
        "location": {
            "contact": {
                "email": "pkarthikeyan@nhs.net", 
                "last_name": "Palaniswamy Karthikeyan"
            }, 
            "contact_backup": {
                "email": "harpreet.grewal@kcl.ac.uk", 
                "last_name": "Harpreet Grewal"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "SE5 9RS"
                }, 
                "name": "Kings College Hospital"
            }, 
            "investigator": {
                "last_name": "Richard J Thompson", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis", 
        "other_outcome": {
            "description": "Adverse events, changes in vital signs, laboratory and other safety parameters from baseline to week 48", 
            "measure": "Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "overall_contact": {
            "email": "info@lumenapharma.com", 
            "last_name": "Sara Barbat, BSN, RN", 
            "phone": "858-461-0694"
        }, 
        "overall_official": {
            "affiliation": "Lumena Pharmaceuticals, Inc.", 
            "last_name": "Alejandro Dorenbaum, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in fasting serum bile acids from baseline to Week 13", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "13 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057718"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change in liver enzymes and pruritus from baseline to Week 13", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "13 weeks"
        }, 
        "source": "Lumena Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Childhood Liver Disease Research and Education Network", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Lumena Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}